JOURNAL OF CHEMOTHERAPY

Scope & Guideline

Exploring Breakthroughs in Infectious Disease Treatment

Introduction

Welcome to your portal for understanding JOURNAL OF CHEMOTHERAPY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1120-009x
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1989 to 2024
AbbreviationJ CHEMOTHERAPY / J. Chemother.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The Journal of Chemotherapy focuses on advancing the understanding and treatment of infectious diseases and cancer through innovative research, clinical trials, and pharmacological studies. The journal emphasizes the importance of chemotherapy and its related fields, including drug resistance, pharmacokinetics, and treatment efficacy.
  1. Chemotherapy Efficacy and Safety:
    Research on the effectiveness and safety profiles of chemotherapy regimens across various cancers, including comparative effectiveness studies of different drug combinations.
  2. Pharmacokinetics and Drug Dosing:
    Studies focusing on the pharmacokinetics of chemotherapeutic agents and antibiotics, including population pharmacokinetic modeling and dosing strategies tailored for specific patient populations.
  3. Drug Resistance Mechanisms:
    Investigation of mechanisms underlying drug resistance in cancer and infectious diseases, including studies on genetic polymorphisms and the role of non-coding RNAs.
  4. Clinical Trials and Real-World Evidence:
    Publication of findings from clinical trials and real-world studies that provide insights into treatment outcomes, adverse effects, and the clinical management of patients receiving chemotherapy.
  5. Infectious Disease Management:
    Research addressing the management of infectious diseases, particularly focusing on antibiotic resistance, treatment strategies, and the role of novel antimicrobial agents.
The Journal of Chemotherapy is adapting to contemporary challenges in oncology and infectious disease management, with several emerging themes reflecting significant shifts in research focus and clinical practice.
  1. Immunotherapy Combinations:
    There is a growing emphasis on studies exploring the combination of immunotherapy with traditional chemotherapy, reflecting the increasing importance of immunotherapeutic strategies in cancer treatment.
  2. Pharmacogenomics and Personalized Medicine:
    Research on pharmacogenomics is gaining traction, as studies investigate how genetic variations affect drug metabolism and response, leading to more personalized chemotherapy regimens.
  3. Antimicrobial Stewardship and Resistance Management:
    An increased focus on antimicrobial stewardship programs and the management of multi-drug resistant pathogens highlights the urgent need for responsible antibiotic use in clinical settings.
  4. Real-World Evidence and Outcomes Research:
    Emerging trends include the collection and analysis of real-world data to assess treatment efficacy and safety, providing more comprehensive insights into patient outcomes outside of controlled clinical trials.
  5. Targeted Therapies and Novel Agents:
    Research into targeted therapies and the development of novel agents is on the rise, as the field shifts towards more specific and effective treatment options for various malignancies.

Declining or Waning

While the Journal of Chemotherapy continues to publish a wide range of impactful research, certain themes appear to be declining in prominence over recent years. These waning scopes indicate shifts in research focus or changes in treatment paradigms.
  1. Traditional Chemotherapy Alone:
    There is a noticeable decline in studies focusing solely on traditional chemotherapy regimens without combination therapies or novel agents, as the field increasingly emphasizes integrated approaches involving immunotherapy and targeted therapy.
  2. Single-Agent Studies:
    Research dedicated to single-agent chemotherapy efficacy is becoming less common, with a trend towards combination therapies that leverage synergistic effects for improved patient outcomes.
  3. Basic Science Research without Clinical Relevance:
    Basic science papers that do not translate into clinical applications or trials are less frequently published, reflecting a shift towards more clinically relevant research that addresses immediate patient care challenges.
  4. Older Antibiotic Classes:
    Research focusing on older classes of antibiotics is decreasing, as new agents and combination therapies gain attention due to rising antibiotic resistance and the need for more effective treatment strategies.

Similar Journals

INVESTIGATIONAL NEW DRUGS

Driving Discoveries in Oncology and Pharmacology
Publisher: SPRINGERISSN: 0167-6997Frequency: 6 issues/year

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Unveiling the Future of Chemotherapy and Infection Control
Publisher: AMER SOC MICROBIOLOGYISSN: 0066-4804Frequency: 12 issues/year

Antimicrobial Agents and Chemotherapy, published by the American Society for Microbiology, is a leading journal in the fields of Infectious Diseases and Pharmacology. With a rich history dating back to its inception in 1963, this esteemed journal provides a vital platform for the dissemination of innovative research and advances in antimicrobials and therapeutic strategies. Currently holding a remarkable Q1 ranking in multiple categories, including Infectious Diseases and Pharmacology (medical), the journal occupies a prestigious position within its discipline, supported by exceptional rankings in Scopus metrics. As an essential resource for researchers, professionals, and students alike, it aims to foster knowledge exchange and inspire new strategies in combating infectious diseases. While not an open-access journal, it remains influential in shaping clinical applications and public health strategies through its rigorous peer-reviewed publications.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Elevating the standards of pharmacological research and clinical application.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

JOURNAL OF VETERINARY MEDICAL SCIENCE

Elevating Standards in Veterinary Medical Research.
Publisher: JAPAN SOC VET SCIISSN: 0916-7250Frequency: 12 issues/year

JOURNAL OF VETERINARY MEDICAL SCIENCE, published by the Japan Society of Veterinary Science, serves as a critical platform for advancing the field of veterinary medicine. With an ISSN of 0916-7250 and E-ISSN of 1347-7439, this journal covers a broad spectrum of topics relevant to veterinary science, publishing original research, reviews, and case studies that contribute to the scientific knowledge base and clinical practice. Recognized for its quality, the journal has achieved a Q2 ranking in the Veterinary (miscellaneous) category for 2023, placing it within the top 35% of journals in its field as per Scopus rankings. With a convergence of years spanning from 1991 to 2024, it reflects a rich history of scholarly contributions. Researchers, professionals, and students engaged in veterinary science will find valuable insights and advancements within its pages, significantly supporting their work and enhancing veterinary practices globally. The journal is located at the University of Tokyo, and while it does not currently offer open access, it remains an essential resource in veterinary medical literature.

Infection and Drug Resistance

Championing open access for groundbreaking research in infection control.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-6973Frequency: 1 issue/year

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Drug Research

Innovating Tomorrow's Therapeutics Today
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

CHEMOTHERAPY

Advancing the Frontiers of Chemotherapy Research
Publisher: KARGERISSN: 0009-3157Frequency: 4 issues/year

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

JOURNAL OF CLINICAL PHARMACOLOGY

Empowering Healthcare with Evidence-Based Pharmacology
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

CPT-Pharmacometrics & Systems Pharmacology

Exploring the future of drug development and patient safety.
Publisher: WILEYISSN: 2163-8306Frequency: 12 issues/year

CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.

International Journal of Antimicrobial Agents

Leading the Charge in Antimicrobial Research and Development
Publisher: ELSEVIERISSN: 0924-8579Frequency: 12 issues/year

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.